NaoX designs a next‑generation electroencephalography solution that embeds patented, miniaturized EEG sensors into everyday objects such as earbuds to record continuous brain activity. Data are processed with AI software and securely transmitted to neurologists, aiming to simplify electrode placement, enable long‑term real‑life data capture, and ease interpretation. The company’s first clinical target is epilepsy and it plans a 50‑patient clinical trial with Hôpital Fondation Adolphe de Rothschild expected to start by the end of 2022. If results are positive, NaoX aims for CE marking and commercialization in Europe and the U.S. by the end of 2023. The business model relies on reimbursement per act by French social security and complementary health insurers. NaoX says it will roughly double headcount to about twenty employees by the end of the year.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2022